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ABSTRACT 
Introduction:  This study was carried out in the direction of 
personalized medicine, based on identifying the genetic characteristics 
of patients, which can affect the pathogenesis of the disease and the 
effectiveness of pharmacotherapy. 
Research tasks: To study of the polymorphism of the cytochrome 
CYP2C9*2 C430T gene in patients with stable angina pectoris and to 
evaluate the significance of this factor in pathogenesis of the disease. 
Material and Methods: A study of 90 patients with stable angina 
pectoris was performed. The polymerase chain reaction was used to 
determine the gene polymorphisms of cytochrome CYP2C9*2 C430T. 
The condition of DNA was studied by the method of DNA comet 
assay. 
Results and Discussion: The presence of gene polymorphisms by the 
alleles CYP2C9*2 C430T was found. They revealed a more severe 
clinical condition of patients with pathological genes by the alleles 
CYP2C9*2 C430T (CT genotype) in comparison with patients with  
 
normal genotype for this allele (CC): a higher functional class of angina 
pectoris, overweight, blood hypercoagulability, an increased level of 
personal anxiety and greater DNA damage. 
Conclusion: polymorphism of the cytochrome CYP2C9*2 C430T gene 
is essential in the pathogenesis of angina pectoris: in patients with the 
pathological genotype of cytochrome CYP2C9*2 C430T gene there 
were revealed more severe clinical condition. 
Keywords: polymorphism of the gene CYP2C9*2 C430T, stable angina 
pectoris, pathogenesis, personalized pharmacotherapy. 
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INTRODUCTION 
Diseases of the cardiovascular system remain leaders in 
prevalence and mortality, despite all the efforts of doctors to 
follow patient management protocols and prescribe 
medications according to accepted standards [1,2]. Perhaps 
the effectiveness of pharmacotherapy may increase if the 
principles of personalized medicine are introduced in the 
treatment of patients with cardiovascular pathology [3,4]. 
Personalized pharmacotherapy based on identifying the 
genetic characteristics of patients is considered one of the 
top priorities in the development of modern medicine [5]. 
Toda , the main base of drugs prescribing personalization is 
considered the knowledge about the genetic polymorphism 
of drugs biotransformation system [6]. One of such 
clinically significant enzymes of biotransformation is 
cytochrome CYP2C9, which is a protein with a molecular 
weight of 55 kDalton, consisting of 490 amino acid residues. 
The gene of this enzyme is located in the locus 10q24.1.24.3 
of the 10th chromosome [7]. Cytochrome CYP2C9 is 
synthesized in liver cells and participates in 
biotransformation of 10% of therapeutically important 
drugs such as anticoagulant warfarin, anticonvulsant 
phenytoin, antidiabetic drug tolbutamide, nonsteroidal anti-
inflammatory drugs (ibuprofen, diclofenac, etc.), losartan, 
etc. [8,9,10]. The pathological gene of cytochrome 
CYP2C9*2, causes the synthesis of the enzyme with altered 
catalytic activity (only 12% of the activity of normal 
CYP2C9) [6]. Therefore, carriers of the variant CUR2C9*2 
are considered as "slow" metabolizers in both homozygous 
and heterozygous states: they have a reduced metabolism of 
drugs, which accumulate in high concentrations in the body, 
which can lead to undesirable drug reactions, including 
intoxication [11]. Along with the function of 
biotransformation of xenobiotics, cytochrome CYP2C9 also 
has the function of synthesizing from the polyunsaturated 
fatty acids of cell membranes of eicosanoids - local action 
hormones, highly active mediators, which take part in 
various processes, in particular, in hemostasis and 
vasodilation [12]. The ability of vessels to vasodilation is 
largely determined by the functional state of the 
endothelium. Endothelium of the vessels is the target organ 
for pharmacological correction of cardiovascular pathology 
both in the clinic and in the experiment 
[13,14,15,16,17,18,19,20,21,22,23,24]. In this regard, the 
study of polymorphism of genes that potentially affect the 
state of the vascular endothelium may be of scientific and 
practical interest. 
The purpose of this study was to study of the polymorphism 
of the cytochrome CYP2C9*2 C430T gene in patients with 
stable angina pectoris and to evaluate the significance of this 
factor in pathogenesis of the disease. 
 
MATERIALS AND METHODS  
A total of 90 patients with IHD: stable angina pectoris were 
examined: 63 men and 27 women aged from 37 to 81 years 
(mean age of patients was 59.26 ± 0.74 years). Clinical 
examination of patients in the initial status was carried out, 
when they entered the cardiology departments of the 
Belgorod Regional Clinical Hospital of St. Joasaph. Each 
participant was acquainted with the research program and 
signed informed consent. In the majority of patients angina 
pectoris was associated with hypertension - 80 (89.4%), 
rhythm disorders - 22 (24.4%), postinfarction 
cardiosclerosis - 44 (48.8%), chronic heart failure - 85 
(94.4%), in some - with type II diabetes - 21 (23.1%). The 
diagnosis of stable angina pectoris was verified after clinical, 
instrumental, laboratory examination in accordance with 
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the recommendations of the European Society of Cardiology 
(ESC) (2013) [1]. 
The program of examination of patients included the 
implementation of general clinical methods of investigation, 
instrumental and laboratory, including electrocardiography, 
echodoplercardiography, coronary angiography, treadmill 
test, general and biochemical blood tests with determination 
of coagulogram, glucose, potassium, creatinine and other 
parameters according to the recommendations of the ESC 
(2013) [1].  
Gene polymorphisms of  CYP2C9*2 C430T was determined 
by polymerase chain reaction using presets reagents of firm 
"Liteh" (Russia) in the Center of genomic selection of 
Belgorod State University. DNA was isolated from blood 
leukocytes from patients. 
The condition of DNA was studied by the method of DNA 
comet assay in the Center of genomic selection of the 
Belgorod State University. The number of damaged cells (%) 
and the maximum degree of DNA damage (1-4 units) were 
determined by the method of DNA comet assay [25].  
In the summary tables only reliable data were entered for 
further analysis. The statistical processing of the material 
was carried out by the method of variational statistics. The 
difference between the two groups was assessed according to 
Student's t-test. The results were considered statistically 
significant at p <0.05. The criterion 2 was used to estimate 
the correspondence of the sample distribution to 
predetermined distributions (the Hardy-Weinberg law). To 
evaluate the results of the DNA comet ssay method, 
CometAssay software was used. During the calculations, the 
programs "Microsoft Excel 2007" and "SPSS for Windows 
11.0" were used. 
 
RESULTS AND DISCUSSION 
When analyzing the CYP2C9*2 C430T gene, 75 people 
(83%) were found to be homozygous for the normal allele 
(CC genotype), and 15 people (17%) were heterozygous 
(genotype CT), i.e. together with the normal allele are 
pathological one (Figure 1.). Homozygous people with the 
pathological allele (TT genotype) were not found in the 
sample. Thus, the frequency of occurrence of the 
pathological allele is 0.092, and the normal one is 0.908. 
There is a small excess of heterozygotes (coefficient of 
inbreeding F = -0.102), as well as a low value of the index of 
genetic variability of the Shannon index (I = 0.308). 
However, in this case the genotypic structure of the sample 
under study is generally consistent with the Hardy-
Weinberg law ( 2 = 0.953, P = 0.329, Df = 1), which allows 
us to speak about the relative stability of the population for a 
given gene. 
 
 
Figure 1: Electrophoregram of polymorphism of the gene CYP2C9 * 2 C430T in patients with ischemic heart disease. 
Note: The arrows denote heterozygotes along the pathological allele of the CT. The unmarked positions correspond to 
homozygotes over the normal CC allele. 
 
A comparative analysis was performed between groups of 
patients with the normal and pathological gene CYP2C9*2 
C430T. A number of significant differences were found 
(Tables 1,2.). In the carriers of the pathological cytochrome 
CYP2C9*2 C430T gene (CT genotype), the following 
features were observed: a higher functional class of angina, 
excess body weight, a tendency to  hypercoagulation of 
blood (despite the fact that all patients took antiplatelet 
agents), a significant relationship with the psychological 
profile - increased the level of personal anxiety, the DNA in 
the original status is more damaged. 
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Table 1: Comparative analysis of groups of patients with stable angina pectoris having a normal and pathological gene 
CYP2C9*2 C430T 
Index Patients with 
normal 
genome ( ) 
Patients with a 
pathological 
gene (CT) 
 
 
Weight, kg 85.03±2.07 99.24±4.46 0.002 
Quetelet index, kg / m2 29.90±0.65 33.14±1.37 0.020 
Prothrombin index, % 96.29±1.22 100.00±0 0.003 
international normalized attitude 1.07±0.03 1.00±0 0.036 
DNA: the number of damaged cells, % 3.43±1.13 11.00±3.21 0.020 
Comment: the reliability of the differences was assessed by the Student's t-test 
 
Table 2: Comparative analysis of groups of patients with stable angina pectoris having a normal and pathological gene 
CYP2C9*2 C430T 
Index Patients with normal 
genome ( ) 
Patients with a 
pathological gene (CT) 
 
 
Functional class of angina pectoris 2.33/ 
3.00 (2.00; 3.00) 
2.79/ 
3.00 (2.00; 3.00) 
0.070 
The degree of obesity 0.64/ 
0.00 (0.00; 1.00) 
1.24/ 
1.00 (0.00; 2.00) 
0.039 
Personal anxiety, scores 48.28/ 
47.00 (41.50; 54.50) 
53.14/ 
52.50 (47.75; 58.25) 
0.061 
DNA: the maximum degree of 
damage 
1.60/ 
2.00 (0.50; 2.00) 
2.45/ 
2.00 (2.00; 3.00) 
0.023 
Comment: The numerator is the arithmetic mean, the denominator is the median, 25% and 75% quartile. The reliability of 
the differences was evaluated according to the Mann-Whitney U criterion. 
 
As mentioned above, cytochrome CYP2C9 has the function 
of biotransformation of xenobiotics and the function of 
synthesizing from the polyunsaturated fatty acids of cell 
membranes of eicosanoids - local action hormones, highly 
active mediators, which take part in various processes, in 
particular, in hemostasis and vasodilation [12]. The 
biochemistry of the reaction is as follows: under the action 
of phospholipase A2 from phospholipids of endothelial cell 
membranes, arachidonic acid is released, which in three 
ways is converted into various eicosanoids-prostaglandins 
under the action of cyclooxygenase, leukotrienes by 
lipoxygenase and epoxyicosotriene acids by cytochromes via 
the P450 monooxygenase pathway. These epoxyicosotriene 
acids (EETs) reduce blood clotting, reduce platelet 
aggregation, produce vasodilation, stimulate angiogenesis, 
have an anti-inflammatory effect, and also protect the heart 
from "damage" in ischemia-reperfusion. EETs produce these 
functional effects by activating receptor-mediated signaling 
pathways and ion channels [12].  
The presence of the pathological CYP2C9*2 gene in humans 
causes the synthesis of the so-called "slow" enzyme of 
cytochrome 2C9, which in turn leads not only to a decrease 
in the biotransformation rate of drugs, as mentioned above 
[11], but also to a violation of eicosanoid synthesis, which 
can lead to increased blood clotting, increased platelet 
aggregation, vasoconstriction, pro-inflammatory effects 
(excessive formation of free radicals of oxygen). The 
phenomenon of association of the presence of the 
pathological gene CYP2C9*2 with a higher functional class 
of angina in patients with ischemic heart disease, the 
tendency of blood to hypercoagulability, greater DNA 
damage, can be explained by a significant decrease in the 
synthesis of eicosanoids-epoxyoxy-isotrenic acids and 
activation of free-radical oxidation, which can destroy DNA. 
Excess body weight contributes to stagnation of blood and 
its thickening, increased personal anxiety is a known risk 
factor for cardiovascular disease [26,27]. In other words, 
according to our study, the reduced activity of cytochrome 
CYP2C9 observed in carriers of the pathological gene 
CYP2C9*2 C430T is associated with a more severe course of 
angina pectoris.  
 
CONCLUSION 
Polymorphism of the cytochrome CYP2C9*2 C430T gene is 
essential in the pathogenesis of angina pectoris: in patients 
with the pathological genotype of cytochrome CYP2C9*2 
C430T gene there were revealed more severe clinical 
condition: a higher functional class of angina pectoris, 
overweight, blood hypercoagulability, an increased level of 
personal anxiety and greater DNA damage. The obtained 
results can be used in planning personalized approaches to 
pharmacotherapy of patients with stable angina pectoris. 
 
MAIN FINDINGS 
1. In the study of cytochrome CYP2C9*2 C430T gene 
polymorphism the relative stability of the population 
for this gene was found: 75 patients (83%) were found 
to be homozygous for the normal allele (CC 
genotype), 15 patients (17%) were heterozygous 
(genotype CT) and no any homozygous patient with 
the pathological allele (TT genotype) was found. 
2. In patients with stable angina pectoris having a 
pathological cytochrome CYP2C9 * 2 C430T gene (CT 
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genotype), in comparison with patients with normal 
genotype for this allele (CC), a higher functional class 
of angina pectoris, overweight, blood 
hypercoagulability, an increased level of personal 
anxiety and greater DNA damage were revealed. 
 
REFERENCES 
1. Montalescot, G., Sechtem, U., Achenbach S. [et al.], 
2013. Guidelines on the management of stable angina 
pectoris: executive summary: the task force on the 
management of stable angina pectoris of the European 
Society of Cardiology. Eur. Heart J., 34:2949-3003. 
2. Tsukanova KO, Fitilev SB, Vozzhaev AV, Shkrebneva 
II, Klyuev DA, 2018. Analysis of changes in 
pharmacotherapy of stable angina over the five-year 
period at specialized out-patient level of medical care 
(pharmacoepidemiological study). Research Results in 
Pharmacology, 4(2): 47-58. 
3. .Romashchenko, OV, 2019) Influence of cytoflavin on 
apoptosis of blood leukocytes in patients with 
ischemic heart disease depending on the 
polymorphism of cytochrome CYP2C9 gene 
according to in vitro testing data.  Eksperimental'naya 
i Klinicheskaya Farmakologiya, 82(1): 16-21. 
4. Romashchenko, OV, 2018. Influence of cytoflavin on 
the DNA of blood leukocytes of patients with ischemic 
heart disease depending on the polymorphism of the 
endothelial nitric oxide synthase gene. 
Eksperimental'naya i Klinicheskaya Farmakologiya, 
81(6): 14-19. 
7. Petrov, VI., Shishimorov, IN., Magnitskaya, O.V., 
Tokachev, BE,2016. Personalized medicine: the 
evolution of methodology and problems of practical 
implementation. Bulletin of Volgograd State Medical 
University. 1 (57): 3-11. (In Russian). 
8. Sychev, DA, Ramenskaya, GV, Ignatiev, IV, Kukes, 
VG, 2007. Clinical pharmacogenetics: Textbook 
/edited by V.G. Kukes, N.P. Bochkova. - Moscow: 
GEOTAR-Media, - 248p. (in Russian) 
9. Maharin OA., 2012. The distribution of the genotypes 
CYP1A1 (Ile462Val), CYP2C9 * 2, CYP2B6 * 2, 
CYP2B6 * 6, CYP3A4 * 1B among residents of Rostov-
on-Don. Living and biosidic systems, 1. URL: 
http://www.jbks.ru/archive/issue-1/article-9. (in 
Russian) 
10.  Lee C., Pieper JA., Frye R et al., 2003. Tolbutamide, 
flurbiprofen and losartan as probes of CYP2C9 
activity in humans. J. Clin. Pharmacol., 43 (1): 84-91 
11. Rettie AE., Jones JP, 2005. Clinical and toxicological 
relevance of CYP2C9: Drug-drug interactions and 
pharmacogenetics. Annu. Rev. Pharmacol. Toxicol., 
45: 477-494. 
12. Sanderson S., Emery J., Higgins J, 2005. CYP2C9 gene 
variants, drug dose, and bleeding risk in warfarin-
treated patients: a HuGEnet systematic review and 
meta-analysis. Genet. Med., 7(2): 97-104. 
13. Korchagina RP, Osipova LP, Vavilova NA, Voronina 
EN, Filippenko ML, 2011. Genetic polymorphism of 
cytochrome P450 2C9, involved in the metabolism of 
drugs in indigenous populations of the North Siberia. 
Bulletin of the SB RAMS, 31 (6): 39-44 (in Russian) 
14. Arthur A. Spector, Hee-Yong Kim,  2015. Cytochrome 
P450 epoxygenase pathway of polyunsaturated fatty 
acid metabolism. Biochim. Biophys. Acta, 1851(4): 
356 365. 
15. Skachilova, S.Y., Kesarev, O.G., Danilenko, L.M., 
Bystrova, N.A., Dolzhikov, A.A., Nikolaev, S.B., 2016. 
Pharmacological correction of L-NAME-induced 
oxide deficiency with derivatives of 3-(2,2,2-
trimethylhydrazinium) propionate. Research result: 
pharmacology and clinical pharmacology, 1 (2): 36-41. 
16.  Molchanova O.V., Pokrovskaya T.G., Povetkin S.V., 
K.M. Reznikov, 2016. Endothelioprotective property 
of the combination of the thioctic acid and 
rosuvastatin shown in the endothelial dysfunction 
models. Research result: pharmacology and clinical 
pharmacology, 2, 1 (2): 9-15.  
17.  Korokin MV, Pokrovskii MV, Kochkarov VI, 
Pokrovskaya TG, Gureev VV, 2014. Endothelial and 
cardio protective effects of tetrahydrobiopterin, L-
norvaline, L-arginine and their combinations by 
simulation of hyperhomo-cysteine induced 
endothelial dysfunction. Research Journal of 
Pharmaceutical, Biological and Chemical Sciences, 
5(6): 1375-1379 
18. Soldatov VO, Shmykova EA, Pershina MA, 
Ksenofontov AO, Zamitsky YM, Kulikov AL, 
Peresypkina AA, Dovgan AP, Belousova YV, 2018. 
Imidazoline receptors agonists: possible mechanisms 
of endothelioprotection. Research Results in 
Pharmacology 4(2): 11-18. 
19. Ragulina V, Kostina D, Dovgan A, Burda Y, 
Nadezhdin S, 2017. Nuclear factor kappa b as a 
potential target for pharmacological correction 
endothelium-associated pathology. Research Results 
in Pharmacology, 3(1): 114-124.   
20. Voronkov AV, Pozdnyakov DI, 2018. 
Endotheliotropic activity of 4-hydroxy-3,5-di-tret-
butylcinnamic acid in the conditions of experimental 
cerebral ischemia. Research Results in Pharmacology, 
4(2): 1-10.  
21. Pokrovskii, MV, Korokin, MV, Kudryavtsev, 
KV, Pokrovskaya, TG, Gudyrev, OS, Gureev, 
VV, Korokina, LV, Povetkin, SV,2017. Study of 
Endothelial Protective Activity of Phenol-Derived 
Thrombin and Arginase-2 Inhibitors KUD-259 and 
KUD-974. Bull Exp Biol Med., 163(4):436-438. 
22.  
AA, Proskuriakova EV, Korokin MV, Gudyrev OS, 
Belous AS, Kochkarov VI, Danilenko LM, Levashova 
OV, Mal'tseva NV, Polianskaia OS, 2012. Correction 
of endothelial dysfunction by L-arginine under 
experimental pre-eclampsia conditions. Eksp Klin 
Farmakol.,75(2):14-6. [Article in Russian] 
23. Gumanova NG, Artyushkova EB, Metel'skaya VA, 
Kochkarov VI, Pokrovskaya TG, Danilenko LM, 
Korneev MM, Pokrovskii MV, Pashin EN, 2007. Effect 
of antioxidants pQ510 and resveratrol on regulatory 
function of the endothelium in rats with modeled 
Olesya V. Romaschenko et al / Polymorphism of CYP2C9 Gene in Patients with Stable Angina Pectoris and its Significance in 
Pathogenesis of the Disease 
 
20                                                                            Systematic Review Pharmacy                                                  Vol 11, Issue 6, 2020 
arterial hypertension. Bulletin of Experimental 
Biology and Medicine, 143(6): 678-681. 
24. Pokrovskii MV, Kochkarov VI, Pokrovskaya TG, 
Artyushkova EB, Pashin EN, Danilenko LM, Korokin 
MV, Belous AS, Korokina LV, Malykhin VA, 
Zaloznykh YI, Brusnik MS, Zhavbert ES, 2009. 
Comparative study of potential endothelioprotectors 
and impaza in modeled nitric oxide deficiency. Bull 
Exp Biol Med., 148(3):514-7. [Article in English, 
Russian] 
25. 
Artiushkova EB, Gureev VV, 2009. Experimental 
study of cardioprotective and endothelioprotective 
action of macrolides and azalides. Experimental and 
Clinical Pharmacology. Eksperimental'naia i 
Klinicheskaia Farmakologiia, 72(2): 29-31 [in Russian] 
26. Korokin MV, Pokrovsky MV, Novikov OO, Gureev 
VV, Denisyuk TA, Korokina LV, Polyanskaya OS, 
Ragulina VA, Pokrovskaya TG, Danilenko LM, Belous 
AS, 2011. Effect of L-arginine, vitamin B6 and folic 
acid on parameters of endothelial dysfunction and 
microcirculation in the placenta in modeling of L-
NAME-induced NO deficiency. Bulletin of 
Experimental Biology and Medicine, 152(1): 70-72. 
27. Collins, AR., Oscoz, AA., Brunborg G. et al., 2008. The 
comet assay: topical issues. Mutagenesis, 23:143-151. 
28. Psheninnikova, MG, 2000. The phenomenon of stress. 
Emotional stress and its role in pathology. 
Pathological physiology and experimental therapy, 4: 
21-31. 
29. Psheninnikova, MG, 2001. The phenomenon of stress. 
Emotional stress and its role in pathology (continued). 
Pathological physiology and experimental therapy, 1: 
26-31. 
